Seres Therapeutics (MCRB) Tops Q3 EPS by 94c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of $0.94. Revenue for the quarter came in at $350 thousand.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• Walmart (WMT) PT Lowered to $130 at UBS as Investment Narrative's Competing Dynamics